M2 PHARMA-February 21, 2018-PharmaMar Antibody Conjugate Increases PFS in HER2-expressing Breast, Ovarian, and Gastric Cancers Compared to Trastuzumab
M2 EQUITYBITES-February 14, 2018-EU approves Celltrion's trastuzumab
There is a high unmet medical need in patients that have HER2-positive MBC and have progressed on trastuzumab
The first cohort, HER2-positive MBC patients who are progressing on anti-HER2 therapies including TDM-1, will receive MCLA-128 in combination with trastuzumab
Our credibility has been further endorsed by the recent USFDA approval of our Biosimilar Trastuzumab
, which is also the first in the US.
is an antibody that blocks the HER2 receptor, and adjuvant trastuzumab
has been shown to increase overall survival (OS) and disease-free survival (DFS) in HER2-positive patients, but is associated with a risk of adverse cardiac events.
Liu therefore tapped Taiwan's Bureau of National Health Insurance (BNHI) population-representative database of 1,629 newly diagnosed IABC patients between 2004 and 2006 who received at various time periods the cancer drugs capecitabine sequential to anthracycline-plus-taxane-based regimens (ATC) and trastuzumab
sequential to anthracycline-plus-taxane-based regimens (ATT) as second-line treatment.
In the trial of trastuzumab
in gastric adenocarcinoma (ToGA), all patients were dual tested (ie, samples underwent both immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) and if either was positive, they were eligible for randomization.
FOLLOWING the success of trastuzumab
, Roche brings the latest innovations in the treatment of HER2-positive breast cancer, namely pertuzumab and trastuzumab
emtansine (T-DM1), which can provide new hope for women to continue to have options when the disease gets worse.
alone or combined with first-line chemotherapy in phase III clinical trials has given better overall response (OR), time to progression (TP) and OS rates than chemotherapy alone in ErbB2+MBC patients (1316).
Significant advancements in breast cancer treatment occurred in two hallmark eras; hormonal therapy was introduced in the 1980s as a treatment for estrogen or progesterone positive breast cancer, and trastuzumab
was introduced in the 1990s as a targeted therapy in the treatment of HER2- positive breast cancer.
and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity.